Kalaris Therapeutics, Inc.KLRS
± MixedCapitalrelevance
Appointment of a new CFO with capital markets experience, but stock fell 5.25% in pre-market, indicating mixed market reaction.
Impact on stocks 1
Health Care
Kalaris Therapeutics, Inc.Kalaris Therapeutics has appointed Liisa Bayko as chief financial officer. Bayko brings more than two decades of experience in biotechnology finance, strategy, and capital markets, most recently serving as managing director and senior biotechnology analyst at Evercore ISI. Shares of Kalaris Therapeutics fell 5.25 percent to $4.15 in pre-market trading.
Kalaris Therapeutics, Inc.Appointment of a new CFO with capital markets experience, but stock fell 5.25% in pre-market, indicating mixed market reaction.